Wednesday, October 14, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 16, 2026

Bitcoin Bear Market Not Over Yet, Says Analyst: 'My Target Price For Going All-In Is....'

View original at finance.yahoo.com
Bitcoin Bear Market Not Over Yet, Says Analyst: 'My Target Price For Going All-In Is....' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bitcoin's rebound to $74,000 should not be interpreted as the end of the bear market

    60% confidence

  • It's okay to buy some BTC now, but traders should not panic if price drops 20-30% after buying

    60% confidence

  • The ongoing bear market is not over as liquidity has not fully recovered

    60% confidence

  • Don't overinterpret Bitcoin's recent surge alongside oil's pullback

    60% confidence

  • Oil's decline attributed to mean reversion from overbought levels while Bitcoin's surge reflected rebound from short-term oversold conditions

    60% confidence

  • The $60,000-$70,000 range is a good zone for dollar-cost averaging but not necessarily the time to go all-in

    60% confidence

  • Target price for going all-in on Bitcoin is $50,000

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com
Bitcoin Bear Market Not Over Yet, Says Analyst: 'My Target Price For Going All-In Is....' — Source | Via News | Via News